We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Reply to the Letter to the Editor in response to "Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal".
- Authors
Meisel, Andreas; Baggi, Fulvio; Behin, Anthony; Evoli, Amelia; Kostera‐Pruszczyk, Anna; Mantegazza, Renato; Juntas Morales, Raul; Punga, Anna Rostedt; Sacconi, Sabrina; Schroeter, Michael; Verschuuren, Jan; Crathorne, Louise; Holmes, Kris; Leite, Maria‐Isabel
- Abstract
Particularly in highly active disease courses, we urgently need blood-based biomarkers for therapy guidance, which could include autoantibody levels, taking into account individual therapy. For example, treatment of AChR autoantibody-positive generalized MG with neonatal Fc receptor inhibitors reveals a strong correlation between clinical severity and AChR autoantibodies, as well as total immunoglobulin G (IgG) levels. Keywords: activity; autoantibody level; biomarker; myasthenia gravis EN activity autoantibody level biomarker myasthenia gravis 1162 1164 3 03/08/23 20230401 NES 230401 Dear Editor, We appreciate the comments from Li et al. [[1]] on aspects of our article entitled "Role of Autoantibody Levels as Biomarkers in the Management of Patients With Myasthenia Gravis: A Systematic Review and Expert Appraisal.".
- Subjects
MYASTHENIA gravis; AUTOANTIBODIES; IMMUNOGLOBULIN G; BIOMARKERS; NEUROMUSCULAR diseases
- Publication
European Journal of Neurology, 2023, Vol 30, Issue 4, p1162
- ISSN
1351-5101
- Publication type
Article
- DOI
10.1111/ene.15690